Pantothenate Kinase Associated Neurodegeneration (Pkan) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pantothenate Kinase-Associated Neurodegeneration (PKAN), formerly known as Hallervorden-Spatz syndrome, is a rare autosomal recessive [neurodegenerative disorder[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases and the most common form of [neurodegeneration with brain iron accumulation (NBIA)[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation--TEMP--/diseases)--FIX--. PKAN is caused by mutations in the PANK2 gene, which encodes the mitochondrial enzyme pantothenate kinase 2, the rate-limiting enzyme in coenzyme A (CoA) biosynthesis 1(https://www.ncbi.nlm.nih.gov/books/NBK430689/). The disease is characterized by progressive dystonia, dysarthria, rigidity, and pigmentary retinal degeneration, with pathological iron accumulation in the globus pallidus and substantia nigra. [10]
PKAN has an estimated incidence of 1-3 per million population and accounts for approximately 35-50% of all NBIA cases 2(](https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/). The disease presents in two main forms: classic PKAN with early childhood onset (before age 6) and rapid progression, and atypical PKAN with later onset (after age 10) and slower progression. The distinctive "eye of the tiger" sign on brain MRI -- a hyperintense center surrounded by a hypointense rim in the globus pallidus on T2-weighted imaging -- is highly characteristic and serves as an important diagnostic marker 3(https://www.ncbi.nlm.nih.gov/books/NBK1490/).
The disease was originally named Hallervorden-Spatz syndrome after Julius Hallervorden and Hugo Spatz, who first described it in 1922. The eponymous name was later abandoned due to the documented involvement of both physicians in Nazi-era euthanasia programs and unethical brain research, and the disorder was renamed PKAN following identification of the causative gene in 2001 4(.
¶ Genetics and Molecular Basis
The PANK2 gene is located on chromosome 20p13 and encodes pantothenate kinase 2, the mitochondrial isoform of pantothenate kinase. This enzyme catalyzes the first and rate-limiting step of coenzyme A (CoA) biosynthesis: the phosphorylation of pantothenate (vitamin B5) to 4'-phosphopantothenate 1(https://www.ncbi.nlm.nih.gov/books/NBK430689/).
The PANK2 gene product is the only pantothenate kinase isoform targeted to mitochondria, where CoA is essential for the tricarboxylic acid (TCA) cycle, fatty acid oxidation, and numerous other metabolic reactions. Between 4% and 9% of all cellular metabolic activities rely on CoA as a cofactor 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8861153/).
Over 150 pathogenic PANK2 variants have been identified:
- Null (loss-of-function) mutations: Homozygous or compound heterozygous null alleles (frameshifts, nonsense, splice-site mutations) cause complete loss of PANK2 activity and are associated with the classic, severe form of PKAN 3(https://www.ncbi.nlm.nih.gov/books/NBK1490/).
- Missense mutations: Point mutations that result in amino acid substitutions with residual enzyme activity are more commonly associated with atypical PKAN and later onset.
- Common variants: The c.1561G>A (p.Gly521Arg) and c.1583C>T (p.Thr528Met) mutations are among the most frequently identified variants in European populations.
- Genotype-phenotype correlations: Disease severity generally correlates with the degree of residual PANK2 enzyme activity. Patients with two null alleles typically exhibit earlier onset and more rapid decline 6(https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.848919/full).
PKAN follows autosomal recessive inheritance. Carrier parents have a 25% chance of having an affected child per pregnancy. Carrier testing and prenatal diagnosis are available for families with known mutations.
The primary biochemical defect in PKAN is impaired CoA biosynthesis in mitochondria:
- Reduced CoA synthesis: Deficient PANK2 activity leads to decreased mitochondrial CoA levels, impairing multiple CoA-dependent metabolic pathways including the TCA cycle, fatty acid beta-oxidation, and heme synthesis 5(https://pmc.ncbi.nlm.nih.gov/articles/PMC8861153/).
- Accumulation of cysteine-containing substrates: The deficiency in the CoA pathway leads to accumulation of N-pantothenoyl-cysteine and free cysteine in the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--.
- Iron chelation by cysteine: Accumulated cysteine chelates iron, and the resulting cysteine-iron complexes undergo Fenton chemistry, generating [reactive oxygen species ([ROS[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- and causing oxidative tissue damage.
- Lipid metabolism disruption: CoA deficiency impairs fatty acid synthesis and degradation, contributing to membrane instability and the accumulation of lipofuscin-like deposits.
The hallmark neuropathological feature of PKAN is iron deposition in the globus pallidus:
- Selective vulnerability: The globus pallidus and [substantia nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra[/brain-regions/[substantia-nigra--TEMP--/brain-regions)--FIX-- are particularly affected, likely because these regions have the highest baseline iron concentrations and are metabolically active.
- Iron-mediated toxicity: Excess iron catalyzes the generation of hydroxyl radicals through the Fenton reaction, causing oxidative damage to lipids, proteins, and DNA 1(https://www.ncbi.nlm.nih.gov/books/NBK430689/).
- [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX--: Recent research has implicated ferroptosis, an iron-dependent form of regulated cell death, in PKAN pathogenesis. Serum metabolomics studies in PKAN patients have revealed ferroptosis-related biomarker signatures 7(https://www.nature.com/articles/s41598-025-94838-w).
- Neuroaxonal dystrophy: Iron deposits are associated with swollen axons (spheroids) and neuroaxonal dystrophy, contributing to progressive neuronal dysfunction.
PANK2 is a mitochondrial enzyme, and its deficiency has direct consequences for mitochondrial function:
- Impaired mitochondrial CoA synthesis reduces [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- and respiratory chain efficiency.
- Decreased beta-oxidation leads to lipid accumulation and altered membrane composition.
- Mitochondrial oxidative stress further damages the organelle, creating a degenerative feedback loop.
Classic PKAN accounts for approximately 75% of cases and presents with the following features:
- Age of onset: Typically before age 6, with most children presenting between ages 3-4.
- Gait disturbance: Usually the first symptom, with progressive difficulty walking due to dystonia and rigidity.
- Progressive dystonia: Generalized dystonia is the hallmark, often beginning in the legs and spreading to involve the trunk, arms, and cranial musculature 2(https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/).
- Oromandibular dystonia: Dystonia of the jaw, face, and tongue leads to dysarthria, feeding difficulties, and drooling.
- Corticospinal tract signs: Spasticity, hyperreflexia, and extensor plantar responses.
- Pigmentary retinopathy: Present in approximately two-thirds of classic PKAN patients; may be detected before neurological symptoms.
- Cognitive decline: Progressive intellectual deterioration, though often less prominent than motor disability.
- Disease course: Rapid progression, with most patients losing the ability to walk within 10-15 years of onset.
Atypical PKAN accounts for approximately 25% of cases:
- Age of onset: After age 10, typically in the teens to early twenties 3(https://www.ncbi.nlm.nih.gov/books/NBK1490/).
- Speech defects: Often the presenting symptom; progressive dysarthria and palilalia.
- Psychiatric symptoms: Depression, anxiety, emotional lability, personality changes, and obsessive-compulsive behaviors may precede motor symptoms by years.
- Movement disorder: Dystonia is present but may be more focal; parkinsonism features (bradykinesia, rigidity) may predominate.
- Cognitive function: May be relatively preserved early, with slower decline than in classic PKAN.
- Pigmentary retinopathy: Less common than in classic PKAN.
- Disease course: Slower progression; patients may retain ambulation for 15-40 years after onset.
- Acanthocytosis: Abnormally shaped red blood cells (acanthocytes) are found in some PKAN patients.
- Seizures: Uncommon but may occur in advanced disease.
- Autonomic dysfunction: Bladder dysfunction, constipation.
- Skeletal deformities: Scoliosis, pes equinovarus secondary to chronic dystonia.
- Brain MRI -- "Eye of the tiger" sign: The pathognomonic finding on T2-weighted MRI is a bilateral symmetric pattern in the globus pallidus consisting of a central hyperintense signal (reflecting gliosis and neuronal loss) surrounded by a rim of hypointensity (reflecting iron deposition). This sign is present in virtually all classic PKAN patients 1(https://www.ncbi.nlm.nih.gov/books/NBK430689/).
- T2/SWI*: More sensitive for detecting iron deposition; shows marked hypointensity in the globus pallidus and substantia nigra.
- Early MRI: In very early disease, the full "eye of the tiger" pattern may not yet be present.
- PANK2 sequencing: Definitive diagnosis requires identification of biallelic pathogenic variants in PANK2. Sequencing detects approximately 98% of mutations in clinically diagnosed patients 3(https://www.ncbi.nlm.nih.gov/books/NBK1490/).
- NBIA gene panels: Multigene panels testing PANK2 alongside other NBIA genes (PLA2G6, C19orf12, WDR45, FA2H, COASY, FTL, CP) are available.
- Electroretinography (ERG): May detect subclinical retinal dysfunction.
- Fundoscopy: May reveal bone-spicule pigmentation characteristic of pigmentary retinopathy.
- Complete blood count with peripheral smear: To detect acanthocytosis.
- Serum ferritin and iron studies: Typically normal (brain iron accumulation is not reflected in peripheral blood).
¶ Treatment and Management
There is no approved disease-modifying therapy for PKAN. Management is symptomatic and supportive:
- Oral medications: Baclofen, trihexyphenidyl, benzodiazepines, and tizanidine.
- Botulinum toxin injections: For focal dystonia, particularly oromandibular and cervical dystonia.
- Intrathecal baclofen: Pump-delivered baclofen for severe generalized dystonia.
- [Deep brain stimulation (DBS)[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--: Bilateral GPi-DBS has shown benefit in some patients. Asymmetric bilateral DBS has been reported as a promising approach in atypical cases 8(https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2024.1448606/full).
- Physical and occupational therapy: To maintain mobility and prevent contractures.
- Speech therapy: For dysarthria and swallowing difficulties.
- Nutritional support: Gastrostomy tube when dysphagia becomes severe.
- Orthopedic interventions: Management of skeletal deformities.
- Visual care: Monitoring pigmentary retinopathy.
- Pantothenate (vitamin B5): High-dose supplementation investigated as substrate-enhancement strategy.
- Pantethine: A CoA precursor that bypasses the PANK2-catalyzed step.
- CoA-Z (fosmetpantotenate): Modified pantetheine derivative; clinical trials showed safety but did not meet primary efficacy endpoints.
- Multitarget supplements: Pantothenate, pantethine, omega-3, and vitamin E combination showed iron reduction in cellular models 9(https://link.springer.com/article/10.1186/s13023-024-03453-x).
- Deferiprone: Oral iron chelator that crosses the [blood-brain barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier[/entities/[blood-brain-barrier--TEMP--/entities)--FIX--. Some evidence of reduced brain iron on MRI, though clinical benefit has been modest.
- AAV-mediated PANK2 gene delivery: Preclinical studies demonstrate feasibility; clinical translation is anticipated.
- Classic PKAN: Progressive course. Most patients become wheelchair-dependent within 10-15 years of onset. Life expectancy is reduced, with death typically in the second to third decade 2(https://rarediseases.org/rare-diseases/pantothenate-kinase-associated-neurodegeneration/).
- Atypical PKAN: Slower progression with variable outcomes. Some patients retain function for decades.
- Both forms are progressive without remission. Quality of life is significantly impacted by dystonia, speech loss, and feeding difficulties.
- [Deep Brain Stimulation (DBS)[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation[/treatments/[deep-brain-stimulation--TEMP--/treatments)--FIX--
The study of Pantothenate Kinase Associated Neurodegeneration (Pkan) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Levi S, Bhatt S. Pantothenate Kinase-Associated Neurodegeneration (PKAN))
- [NORD. Pantothenate Kinase-Associated Neurodegeneration)
- [Gregory A, Hayflick S. Pantothenate Kinase-Associated Neurodegeneration)
- [Wikipedia. Pantothenate kinase-associated neurodegeneration)
- [Thakur N, et al. Redesigning therapies for pantothenate kinase-associated neurodegeneration)
- [Liu S, et al. Novel PANK2 Mutations and Genotype-Phenotype Correlation)
- [Zhou J, et al. Serum metabolomics indicates ferroptosis in PKAN patients)
- [Liu Z, et al. Asymmetric bilateral DBS for PKAN treatment)
- [Alvarez-Cordoba M, et al. Therapeutic approach to PKAN: a pilot study)
- [NBIA Disorders Association. PKAN)
- [Emedicine/Medscape. PKAN)
- [Orphanet. Pantothenate kinase-associated neurodegeneration)